stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) EV/Sales
As of 5 November 2026, GeneDx Holdings Corp. (WGS) trades at a EV/Sales of 4.2×. Over the past ten years it has ranged from −2.2× (December 2021) to 11.7× (November 2025); the current reading is higher than 69% of that period. That is below the Diagnostics & Research industry median of 5.2× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.4× | 30.13% |
| FY2024 | 6.5× | — |
| FY2023 | −0.1× | — |
| FY2022 | −0.5× | — |
| FY2021 | −1.8× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.4× | 7.85% |
| Mar 2026 | 4.1× | (51.47%) |
| Dec 2025 | 8.4× | 12.98% |
| Sep 2025 | 7.5× | 5.74% |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FRNM Freenome, Inc compare | n/m |
| CSTL Castle Biosciences, Inc. compare | 2.1× |
| VCYT Veracyte, Inc. compare | 2.5× |
| OPK OPKO Health, Inc. compare | 2.8× |
| NEO NeoGenomics, Inc. compare | 3.3× |
| WGS GeneDx Holdings Corp. | 4.2× |
| CDNA CareDx, Inc. compare | 7.6× |
| ADPT Adaptive Biotechnologies Corporation compare | 14.6× |
| PSNL Personalis, Inc. compare | 18.6× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement